Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of temsirolimus in combination with
brentuximab vedotin in patients with relapsed and refractory Hodgkin lymphoma.

II. To assess the safety of brentuximab vedotin in combination with temsirolimus in patients
with relapsed and refractory Hodgkin lymphoma.

III. To assess the toxicity profile of this regimen in the above patients.

SECONDARY OBJECTIVES:

I. Determine the overall response rate (ORR) to the combination of brentuximab vedotin and
temsirolimus in relapsed and refractory Hodgkin lymphoma.

II. Evaluate the role of inflammatory markers, such as interleukin (IL)-6, IL-1, tumor
necrosis factor alpha (TNF alpha), and IL-10, as early predictors of treatment response.

OUTLINE: This is a dose-escalation study of temsirolimus.

Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1 and 8 or days
1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21
days for up to 16 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.

Inclusion Criteria:

- Patients must have histologically confirmed cluster of differentiation (CD)30
positive relapsed or refractory Hodgkin lymphoma

- Measurable disease, defined as at least one lesion > 1.5 cm, in the greatest
transverse diameter

- Patients must have failed autologous stem cell transplant or at least 2 prior
cytotoxic regimens for Hodgkin lymphoma

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Life expectancy of greater than 3 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits or < 3 x the upper limit of normal
in patients with Gilbert's disease

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 × institutional upper limit of normal

- Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 40
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Patients must have no evidence of dyspnea at rest, no exercise intolerance, and a
pulse oximetry > 92% while breathing room air

- Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity
(FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass
from Hodgkin's lymphoma (HL); carbon monoxide diffusion capacity (DLCO), FEV1, and
FVC all > 50% predicted value

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while she or her partner is participating in this study, she should
inform her treating physician immediately; men treated or enrolled on this protocol
must also agree to use adequate contraception prior to the study, for the duration of
study participation, and 4 months after completion of temsirolimus and brentuximab
vedotin administration

- Ability to understand and the willingness to sign a written informed consent document

- Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L AND fasting triglycerides =<
2.5 x upper limit of normal (ULN); NOTE: In case one or both of these thresholds are
exceeded, the patient can only be included after initiation of appropriate lipid
lowering medication

- Patients with known human immunodeficiency virus (HIV) infection must have CD4 count
greater than 200; anti-retroviral agents that induce or inhibit cytochrome P450
(CYP)3A4 activity are not allowed

Exclusion Criteria:

- Patients who are eligible for autologous stem cell transplant unless they refuse to
receive autologous stem cell transplant

- Patients who have had chemotherapy or radiotherapy within 3 weeks of registration or
those who have not recovered from adverse events due to agents administered more than
3 weeks earlier; Note: patients are considered enrolled on the study after protocol
registration and not after signing consent

- Patients who have received brentuximab vedotin within 6 months of enrolling on the
study

- Patients who are receiving any other investigational agents

- Patients with known cerebral or meningeal involvement by lymphoma should be excluded
from this clinical trial

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to temsirolimus or brentuximab vedotin

- Patients receiving any medications or substances that are inhibitors or inducers of
CYP3A4 are ineligible

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, uncontrolled diabetes, clinically significant pneumonitis, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with temsirolimus and brentuximab vedotin

- Previous primary progression or grade 3 toxicity on treatment with brentuximab
vedotin

- Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent, except corticosteroids with a daily dosage equivalent to
prednisone =< 20 mg; topical or inhaled corticosteroids are allowed